Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with…
Sarclisa is the first anti-CD38 treatment approved in China for patients with…
Sign in to your account